Cancer therapy using toll-like receptor agonists
AssigneeTriSalus Life Sciences, Inc.
InventorsSteven C. Katz, Bryan F. Cox, David Benjamin Jaroch
Life of this patent
Estimating the term…
Abstract
Embodiments of the present invention provide for methods of treating cancer and methods of delivering toll-like receptor (TLR) agonists to solid tumors in the liver using a locoregional therapy through the vasculature. In one aspect, the present invention relates to a method of treating primary liver cancers such as hepatocellular carcinoma (HCC) and intra-hepatic cholangiocarcinoma (ICC) comprising administering TLR9 agonists to the liver.
Claims18
A method for treating a primary liver cancer comprising administering to a subject in need thereof a therapeutically effective amount of a toll-like receptor 9 (TLR9) agonist having the structure:
- 5′-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3′ (SEQ ID NO:
- 1).
Dependencies are inferred from the claim text.